WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 19, 2018--
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of product candidates
using its proprietary mucus-penetrating particle (MPP) technology, today
announced that it will release fourth quarter and full year 2017
financial results on Monday, March 26, 2018. Kala will host a live
conference call and webcast at 8:00 AM ET to provide a general business
update and discuss the Company’s 2017 financial results.
The dial-in numbers to access the conference call are 866-300-4091 for
domestic callers and 703-736-7433 for international callers. The
conference ID is 7082747. To access a live webcast and subsequent
archived recording of the call, please visit the “Investors & Media”
section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a
biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates. The product candidates are INVELTYS™ (KPI-121 1%)
for the treatment of inflammation and pain following ocular surgery, for
which an NDA has been accepted for review by the FDA, and KPI-121 0.25%
for the temporary relief of the signs and symptoms of dry eye disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180319005365/en/
Source: Kala Pharmaceuticals, Inc.
Investors and Media:
MacDougall Biomedical Communications